The animal model market size has grown strongly in recent years. It will grow from $1.76 billion in 2023 to $1.92 billion in 2024 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to the rising adoption of animal models for biomedical research, surging expenditure and high investments in drug development and discovery, growing focus on precision medicine, and extensive applications of animal models in the healthcare industry.
The animal model market size is expected to see strong growth in the next few years. It will grow to $2.69 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The forecast period's growth is expected to be driven by several factors, including advancements in genetic engineering techniques, a heightened emphasis on personalized medicine, the escalating prevalence of chronic diseases, the growing demand for effective vaccines and therapeutics, and increased investments in biomedical research. Anticipated trends in the forecast period include a surge in the demand for animal models in drug discovery and development efforts, driven by the need for more accurate preclinical testing. Additionally, the physiological similarities between humans and animals are expected to expedite drug development timelines. The increasing consumption of personalized medicine is projected to fuel demand for humanized mice models tailored to individual patient needs. Overall, the market is poised for significant growth due to the rising adoption of animal models for biomedical research across various sectors.
The upsurge in investment activities in pharmaceutical research and development is anticipated to drive the growth of the animal model market. Pharmaceutical research and development constitutes a multifaceted process where scientific inquiry and innovation converge to propel medical advancements. With a growing emphasis on innovative therapies targeting complex diseases, pharmaceutical R&D fuels scientific curiosity and commercial opportunities within the healthcare sector. Animal models play a pivotal role in pharmaceutical R&D by aiding in predicting drug efficacy, safety, and toxicity, offering insights into biological mechanisms, and facilitating the development of new treatments through the replication of human physiological responses and disease progression in controlled environments. For example, data from the European Federation of Pharmaceutical Industries and Associations in June 2023 revealed an increase in pharmaceutical R&D spending across Europe from €39.44 billion ($42,543 million) in 2020 to €44.5 billion ($47,999 million) in 2022, representing a 7.82% growth.
Key players in the animal model market are focusing on the development of innovative products, such as triple-immunodeficient animal models, to enhance the accuracy and reliability of preclinical studies, support advanced biomedical research, and facilitate the development of novel therapies for complex human diseases. Triple-immunodeficient animal models, typically mice, are specially engineered to lack three key immune system components, making them invaluable for studying human diseases and developing new treatments. For instance, Charles River Laboratories International, Inc., a US-based pharmaceutical company, introduced NCG mouse strains in January 2024, offering a triple-immunodeficient mouse model for oncology research. These mice lack functional/mature T, B, and NK cells, making them ideal hosts for xenograft cells, tissues, and human immune system components. NCG mice are particularly useful for research in oncology, immunology, infectious diseases, regenerative medicine, and tissue transplant studies, among others.
In October 2021, Jackson Laboratory, a US-based independent, non-profit biomedical research institution, acquired Charles River Laboratories Japan’s Research Models & Services (RMS) business for $70.9 million. This strategic acquisition aims to enhance the capabilities of Japanese researchers by providing direct access to cutting-edge animal research models, services, and scientific support. Charles River Laboratories Japan, Inc., the previous owner, was a Japan-based provider of research animal models.
Major companies operating in the animal model market are Eurofins Scientific SE, Charles River Laboratories International Inc., Pharmaron Beijing Co Ltd, Inotiv Inc., Biocytogen, Taconic Biosciences Incorporation, Cyagen Biosciences, Trans Genic Incorporation, Crown Bioscience Incorporation, Harbor BioMed, PharmaLegacy, PsychoGenics, Biomere Biomedical Research Models Inc., Genoway S.A, Alloy Therapeutics, Janvier Labs, Hera Biolabs, Ozgene Pty Ltd, Transposagen Biopharmaceuticals Inc., KMT Hepatech Inc., AniLocus Inc., BioXpert, Harlan Sprague Dawley Inc.
North America was the largest region in the animal model market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the animal model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
An animal model refers to a non-human species utilized in scientific research to explore biological processes, investigate disease mechanisms, and assess the effectiveness and safety of novel treatments and interventions. These models serve as invaluable tools for advancing medical knowledge and facilitating the development of new therapies, effectively bridging the gap between fundamental research and clinical practice.
The primary types of animal models include mice, rats, guinea pigs, rabbits, hamsters, and others. Mice, for instance, are small rodents belonging to the family Muridae, typically recognized by their pointed snouts, rounded ears, and elongated, hairless tails. Technologies employed in animal modeling encompass clustered regularly interspaced short palindromic repeats (CRISPR), embryonic stem cell injection, nuclear transfer, among others, and find applications in diverse areas such as drug discovery and development, fundamental research, and more. End users of animal models include research institutes, educational institutions, pharmaceutical companies, and contract research organizations.
The animal model market research report is one of a series of new reports that provides animal model market statistics, including animal model industry global market size, regional shares, competitors with an animal model market share, detailed animal model market segments, market trends and opportunities, and any further data you may need to thrive in the animal model industry. This animal model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The animal model market consists of revenues earned by entities by providing services custom animal model development, animal breeding and colony management, behavioral and neurological testing, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The animal model market consists of sales of genetically engineered models, spontaneous models, induced models, xenograft and allograft models, and environmental models. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The animal model market size is expected to see strong growth in the next few years. It will grow to $2.69 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The forecast period's growth is expected to be driven by several factors, including advancements in genetic engineering techniques, a heightened emphasis on personalized medicine, the escalating prevalence of chronic diseases, the growing demand for effective vaccines and therapeutics, and increased investments in biomedical research. Anticipated trends in the forecast period include a surge in the demand for animal models in drug discovery and development efforts, driven by the need for more accurate preclinical testing. Additionally, the physiological similarities between humans and animals are expected to expedite drug development timelines. The increasing consumption of personalized medicine is projected to fuel demand for humanized mice models tailored to individual patient needs. Overall, the market is poised for significant growth due to the rising adoption of animal models for biomedical research across various sectors.
The upsurge in investment activities in pharmaceutical research and development is anticipated to drive the growth of the animal model market. Pharmaceutical research and development constitutes a multifaceted process where scientific inquiry and innovation converge to propel medical advancements. With a growing emphasis on innovative therapies targeting complex diseases, pharmaceutical R&D fuels scientific curiosity and commercial opportunities within the healthcare sector. Animal models play a pivotal role in pharmaceutical R&D by aiding in predicting drug efficacy, safety, and toxicity, offering insights into biological mechanisms, and facilitating the development of new treatments through the replication of human physiological responses and disease progression in controlled environments. For example, data from the European Federation of Pharmaceutical Industries and Associations in June 2023 revealed an increase in pharmaceutical R&D spending across Europe from €39.44 billion ($42,543 million) in 2020 to €44.5 billion ($47,999 million) in 2022, representing a 7.82% growth.
Key players in the animal model market are focusing on the development of innovative products, such as triple-immunodeficient animal models, to enhance the accuracy and reliability of preclinical studies, support advanced biomedical research, and facilitate the development of novel therapies for complex human diseases. Triple-immunodeficient animal models, typically mice, are specially engineered to lack three key immune system components, making them invaluable for studying human diseases and developing new treatments. For instance, Charles River Laboratories International, Inc., a US-based pharmaceutical company, introduced NCG mouse strains in January 2024, offering a triple-immunodeficient mouse model for oncology research. These mice lack functional/mature T, B, and NK cells, making them ideal hosts for xenograft cells, tissues, and human immune system components. NCG mice are particularly useful for research in oncology, immunology, infectious diseases, regenerative medicine, and tissue transplant studies, among others.
In October 2021, Jackson Laboratory, a US-based independent, non-profit biomedical research institution, acquired Charles River Laboratories Japan’s Research Models & Services (RMS) business for $70.9 million. This strategic acquisition aims to enhance the capabilities of Japanese researchers by providing direct access to cutting-edge animal research models, services, and scientific support. Charles River Laboratories Japan, Inc., the previous owner, was a Japan-based provider of research animal models.
Major companies operating in the animal model market are Eurofins Scientific SE, Charles River Laboratories International Inc., Pharmaron Beijing Co Ltd, Inotiv Inc., Biocytogen, Taconic Biosciences Incorporation, Cyagen Biosciences, Trans Genic Incorporation, Crown Bioscience Incorporation, Harbor BioMed, PharmaLegacy, PsychoGenics, Biomere Biomedical Research Models Inc., Genoway S.A, Alloy Therapeutics, Janvier Labs, Hera Biolabs, Ozgene Pty Ltd, Transposagen Biopharmaceuticals Inc., KMT Hepatech Inc., AniLocus Inc., BioXpert, Harlan Sprague Dawley Inc.
North America was the largest region in the animal model market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the animal model market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the animal model market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
An animal model refers to a non-human species utilized in scientific research to explore biological processes, investigate disease mechanisms, and assess the effectiveness and safety of novel treatments and interventions. These models serve as invaluable tools for advancing medical knowledge and facilitating the development of new therapies, effectively bridging the gap between fundamental research and clinical practice.
The primary types of animal models include mice, rats, guinea pigs, rabbits, hamsters, and others. Mice, for instance, are small rodents belonging to the family Muridae, typically recognized by their pointed snouts, rounded ears, and elongated, hairless tails. Technologies employed in animal modeling encompass clustered regularly interspaced short palindromic repeats (CRISPR), embryonic stem cell injection, nuclear transfer, among others, and find applications in diverse areas such as drug discovery and development, fundamental research, and more. End users of animal models include research institutes, educational institutions, pharmaceutical companies, and contract research organizations.
The animal model market research report is one of a series of new reports that provides animal model market statistics, including animal model industry global market size, regional shares, competitors with an animal model market share, detailed animal model market segments, market trends and opportunities, and any further data you may need to thrive in the animal model industry. This animal model market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The animal model market consists of revenues earned by entities by providing services custom animal model development, animal breeding and colony management, behavioral and neurological testing, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The animal model market consists of sales of genetically engineered models, spontaneous models, induced models, xenograft and allograft models, and environmental models. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Animal Model Market Characteristics3. Animal Model Market Trends and Strategies32. Global Animal Model Market Competitive Benchmarking33. Global Animal Model Market Competitive Dashboard34. Key Mergers and Acquisitions in the Animal Model Market
4. Animal Model Market - Macro Economic Scenario
5. Global Animal Model Market Size and Growth
6. Animal Model Market Segmentation
7. Animal Model Market Regional and Country Analysis
8. Asia-Pacific Animal Model Market
9. China Animal Model Market
10. India Animal Model Market
11. Japan Animal Model Market
12. Australia Animal Model Market
13. Indonesia Animal Model Market
14. South Korea Animal Model Market
15. Western Europe Animal Model Market
16. UK Animal Model Market
17. Germany Animal Model Market
18. France Animal Model Market
19. Italy Animal Model Market
20. Spain Animal Model Market
21. Eastern Europe Animal Model Market
22. Russia Animal Model Market
23. North America Animal Model Market
24. USA Animal Model Market
25. Canada Animal Model Market
26. South America Animal Model Market
27. Brazil Animal Model Market
28. Middle East Animal Model Market
29. Africa Animal Model Market
30. Animal Model Market Competitive Landscape and Company Profiles
31. Animal Model Market Other Major and Innovative Companies
35. Animal Model Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Animal Model Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on animal model market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for animal model? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The animal model market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Animal Type: Mice; Rat; Guinea Pigs; Rabbits; Hamsters; Other Animal Types2) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR); Embryonic Stem Cell Injection; Nuclear Transfer; Other Technologies
3) By Application: Drug Discovery And Development; Basic Research; Other Applications
4) By End User: Research Institutes; Educational Institutes; Pharmaceutical Companies; Contract Research Organizations
Key Companies Mentioned: Eurofins Scientific SE; Charles River Laboratories International Inc.; Pharmaron Beijing Co Ltd; Inotiv Inc.; Biocytogen
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eurofins Scientific SE
- Charles River Laboratories International Inc.
- Pharmaron Beijing Co Ltd
- Inotiv Inc.
- Biocytogen
- Taconic Biosciences Incorporation
- Cyagen Biosciences
- Trans Genic Incorporation
- Crown Bioscience Incorporation
- Harbor BioMed
- PharmaLegacy
- PsychoGenics
- Biomere Biomedical Research Models Inc.
- Genoway S.A
- Alloy Therapeutics
- Janvier Labs
- Hera Biolabs
- Ozgene Pty Ltd
- Transposagen Biopharmaceuticals Inc.
- KMT Hepatech Inc.
- AniLocus Inc.
- BioXpert
- Harlan Sprague Dawley Inc.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 175 |
Published | July 2024 |
Forecast Period | 2024 - 2028 |
Estimated Market Value ( USD | $ 1.92 Billion |
Forecasted Market Value ( USD | $ 2.69 Billion |
Compound Annual Growth Rate | 8.9% |
Regions Covered | Global |